Jingsi Dai

Title: Jingsi Dai: Innovator in Multi-Target Kinase Inhibitors

Introduction

Jingsi Dai is a notable inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of multi-target kinase inhibitors. His work is crucial in addressing various diseases linked to abnormal signal transduction pathways.

Latest Patents

Jingsi Dai holds a patent for a multi-target kinase inhibitor, which includes a pharmaceutical composition and a preparation method for the inhibitor. This innovative compound is designed to effectively inhibit the enzymatic activities of RET, VEGFR3, and PDGFRA. The patent outlines its potential use in treating various cancers, including those of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, as well as distant metastatic cancers, lymphoma, sarcoma, and leukemia. The active ingredients in the pharmaceutical composition comprise 1-50 wt % of the multi-target kinase inhibitor.

Career Highlights

Throughout his career, Jingsi Dai has worked with prominent companies in the biotechnology sector. He has been associated with Guangzhou Liushun Biotechnology Co., Ltd. and Beijing Beikehuaxia Biomedical Technology Co., Ltd. His experience in these organizations has contributed to his expertise in the development of innovative pharmaceutical solutions.

Collaborations

Jingsi Dai has collaborated with notable professionals in his field, including Bing Liu and Yan Wang. These partnerships have enhanced his research and development efforts, leading to advancements in multi-target kinase inhibitors.

Conclusion

Jingsi Dai's contributions to the field of pharmaceuticals, particularly through his patent on multi-target kinase inhibitors, highlight his role as an innovator. His work has the potential to significantly impact the treatment of various cancers and related diseases.